HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy—Updated analysis of antitumor efficacy.

Atsushi Ishiguro,Hiroshi Nakatsumi,Tetsuhito Muranaka,Yasuyuki Kawamoto,Satoshi Yuki,Miki Tateyama,Atsushi Sato,Takuto Miyagishima,Michio Nakamura,Masayoshi Dazai,Hiroyuki Okuda,Yasuo Takahashi,Tomoe Kobayashi,Takashi Kato,Kazuteru Hatanaka,Toraji Amano,Yuh Sakata,Yoshito Komatsu

Journal of Clinical Oncology（2020）

引用 1|浏览17

暂无评分

摘要

108Background: IRIS (irinotecan plus S-1) plus bevacizumab (IRIS/Bev) is one of the standard chemotherapies in Japan for metastatic colorectal cancer (mCRC) as the first-line or second-line therapy...

查看译文

关键词

metastatic colorectal cancer,colorectal cancer,antitumor efficacy,diarrhea,double-blind,hange-shashin-to,second-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要